Corticosteroids in the management of bowel obstruction on a gynecological oncology unit.
The development of gastrointestinal obstruction commonly occurs as a complication of advanced gynecological cancer. While surgery remains the mainstay of treatment for these patients, it is not always feasible, and when it is performed, it does not always resolve the obstruction. In this prospective study of patients presenting to a gynecologic oncology unit, 13 patients were administered 8 mg of dexamethasone subcutaneously or intravenously for a minimum of 3 days to manage the symptoms of bowel obstruction. Nine patients (69%) had a response to this therapy with decreased pain, nausea, and vomiting and improved oral intake. This response was maintained for a median of 31 days, with 7 of the 9 patients maintaining this symptomatic response until death. Mean survival of those responding was 39 days, including a subgroup of patients with extremely limited prognosis who, at their request, were discharged from the hospital in order to die at home. This subgroup had a mean survival of 20 days. The mean survival for nonresponders was 54 days. In patients for whom surgery is not contemplated, corticosteroids may provide a palliative treatment for bowel obstruction secondary to malignancy, provided there are no contraindications.
Philip
J
J
Gynaecological Cancer Centre, Royal Hospital for Women, Barker St., Randwick, New South Wales, Australia.
Lickiss
N
N
Grant
P T
PT
Hacker
N F
NF
D000328:Adult; D000368:Aged; D003907:Dexamethasone / Q000627:therapeutic use*; D005260:Female; D005833:Genital Neoplasms, Female / Q000150:complications*; D005938:Glucocorticoids / Q000627:therapeutic use*; D006801:Humans; D007415:Intestinal Obstruction / Q000188:drug therapy* / Q000209:etiology; D008137:Longitudinal Studies; D008875:Middle Aged; D011446:Prospective Studies
D005938:Glucocorticoids; D003907:Dexamethasone